

# COVID-19 Impact on Global ER Targeted Drugs for Breast Cancer Market Size, Status and Forecast 2020-2026

<https://marketpublishers.com/r/C9782E999321EN.html>

Date: July 2020

Pages: 128

Price: US\$ 3,900.00 (Single User License)

ID: C9782E999321EN

## Abstracts

This report focuses on the global ER Targeted Drugs for Breast Cancer status, future forecast, growth opportunity, key market and key players. The study objectives are to present the ER Targeted Drugs for Breast Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

AstraZeneca

Sanofi

Pfizer

Mylan

Wockhardt

Cipla

Actiza Pharmaceutical

Teva

Shanghai Forward Technology

Bayer

Liaoning Kangtai Pharmaceutical

Fu 'an Pharmaceutical Group

Yangtze River Pharmaceutical Group

Amneal Pharms

Novartis

Intas Pharmaceuticals

Chemo

Accure Labs

Natco

Orion Corporation

Kyowa Hakko Kirin

Market segment by Type, the product can be split into

Tamoxifen

Toremifene

Fulvestrant

Market segment by Application, split into

Hospital

Clinic

Drug Center

Other

Market segment by Regions/Countries, this report covers

North America

Europe

China

Japan

Southeast Asia

India

Central & South America

The study objectives of this report are:

To analyze global ER Targeted Drugs for Breast Cancer status, future forecast, growth opportunity, key market and key players.

To present the ER Targeted Drugs for Breast Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

To strategically profile the key players and comprehensively analyze their development plan and strategies.

To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of ER Targeted Drugs for Breast Cancer are as follows:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

## Contents

### 1 REPORT OVERVIEW

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered: Ranking by ER Targeted Drugs for Breast Cancer Revenue

1.4 Market Analysis by Type

1.4.1 Global ER Targeted Drugs for Breast Cancer Market Size Growth Rate by Type: 2020 VS 2026

1.4.2 Tamoxifen

1.4.3 Toremifene

1.4.4 Fulvestrant

1.5 Market by Application

1.5.1 Global ER Targeted Drugs for Breast Cancer Market Share by Application: 2020 VS 2026

1.5.2 Hospital

1.5.3 Clinic

1.5.4 Drug Center

1.5.5 Other

1.6 Coronavirus Disease 2019 (Covid-19): ER Targeted Drugs for Breast Cancer Industry Impact

1.6.1 How the Covid-19 is Affecting the ER Targeted Drugs for Breast Cancer Industry

1.6.1.1 ER Targeted Drugs for Breast Cancer Business Impact Assessment - Covid-19

1.6.1.2 Supply Chain Challenges

1.6.1.3 COVID-19's Impact On Crude Oil and Refined Products

1.6.2 Market Trends and ER Targeted Drugs for Breast Cancer Potential Opportunities in the COVID-19 Landscape

1.6.3 Measures / Proposal against Covid-19

1.6.3.1 Government Measures to Combat Covid-19 Impact

1.6.3.2 Proposal for ER Targeted Drugs for Breast Cancer Players to Combat Covid-19 Impact

1.7 Study Objectives

1.8 Years Considered

### 2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 ER Targeted Drugs for Breast Cancer Market Perspective (2015-2026)

## 2.2 ER Targeted Drugs for Breast Cancer Growth Trends by Regions

2.2.1 ER Targeted Drugs for Breast Cancer Market Size by Regions: 2015 VS 2020 VS 2026

2.2.2 ER Targeted Drugs for Breast Cancer Historic Market Share by Regions (2015-2020)

2.2.3 ER Targeted Drugs for Breast Cancer Forecasted Market Size by Regions (2021-2026)

## 2.3 Industry Trends and Growth Strategy

2.3.1 Market Top Trends

2.3.2 Market Drivers

2.3.3 Market Challenges

2.3.4 Porter's Five Forces Analysis

2.3.5 ER Targeted Drugs for Breast Cancer Market Growth Strategy

2.3.6 Primary Interviews with Key ER Targeted Drugs for Breast Cancer Players (Opinion Leaders)

## 3 COMPETITION LANDSCAPE BY KEY PLAYERS

### 3.1 Global Top ER Targeted Drugs for Breast Cancer Players by Market Size

3.1.1 Global Top ER Targeted Drugs for Breast Cancer Players by Revenue (2015-2020)

3.1.2 Global ER Targeted Drugs for Breast Cancer Revenue Market Share by Players (2015-2020)

3.1.3 Global ER Targeted Drugs for Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

### 3.2 Global ER Targeted Drugs for Breast Cancer Market Concentration Ratio

3.2.1 Global ER Targeted Drugs for Breast Cancer Market Concentration Ratio (CR5 and HHI)

3.2.2 Global Top 10 and Top 5 Companies by ER Targeted Drugs for Breast Cancer Revenue in 2019

3.3 ER Targeted Drugs for Breast Cancer Key Players Head office and Area Served

3.4 Key Players ER Targeted Drugs for Breast Cancer Product Solution and Service

3.5 Date of Enter into ER Targeted Drugs for Breast Cancer Market

3.6 Mergers & Acquisitions, Expansion Plans

## 4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global ER Targeted Drugs for Breast Cancer Historic Market Size by Type (2015-2020)

4.2 Global ER Targeted Drugs for Breast Cancer Forecasted Market Size by Type (2021-2026)

## **5 ER TARGETED DRUGS FOR BREAST CANCER BREAKDOWN DATA BY APPLICATION (2015-2026)**

5.1 Global ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)

5.2 Global ER Targeted Drugs for Breast Cancer Forecasted Market Size by Application (2021-2026)

## **6 NORTH AMERICA**

6.1 North America ER Targeted Drugs for Breast Cancer Market Size (2015-2020)

6.2 ER Targeted Drugs for Breast Cancer Key Players in North America (2019-2020)

6.3 North America ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)

6.4 North America ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)

## **7 EUROPE**

7.1 Europe ER Targeted Drugs for Breast Cancer Market Size (2015-2020)

7.2 ER Targeted Drugs for Breast Cancer Key Players in Europe (2019-2020)

7.3 Europe ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)

7.4 Europe ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)

## **8 CHINA**

8.1 China ER Targeted Drugs for Breast Cancer Market Size (2015-2020)

8.2 ER Targeted Drugs for Breast Cancer Key Players in China (2019-2020)

8.3 China ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)

8.4 China ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)

## **9 JAPAN**

9.1 Japan ER Targeted Drugs for Breast Cancer Market Size (2015-2020)

- 9.2 ER Targeted Drugs for Breast Cancer Key Players in Japan (2019-2020)
- 9.3 Japan ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)
- 9.4 Japan ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)

## **10 SOUTHEAST ASIA**

- 10.1 Southeast Asia ER Targeted Drugs for Breast Cancer Market Size (2015-2020)
- 10.2 ER Targeted Drugs for Breast Cancer Key Players in Southeast Asia (2019-2020)
- 10.3 Southeast Asia ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)
- 10.4 Southeast Asia ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)

## **11 INDIA**

- 11.1 India ER Targeted Drugs for Breast Cancer Market Size (2015-2020)
- 11.2 ER Targeted Drugs for Breast Cancer Key Players in India (2019-2020)
- 11.3 India ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)
- 11.4 India ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)

## **12 CENTRAL & SOUTH AMERICA**

- 12.1 Central & South America ER Targeted Drugs for Breast Cancer Market Size (2015-2020)
- 12.2 ER Targeted Drugs for Breast Cancer Key Players in Central & South America (2019-2020)
- 12.3 Central & South America ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)
- 12.4 Central & South America ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)

## **13 KEY PLAYERS PROFILES**

- 13.1 AstraZeneca
  - 13.1.1 AstraZeneca Company Details
  - 13.1.2 AstraZeneca Business Overview and Its Total Revenue
  - 13.1.3 AstraZeneca ER Targeted Drugs for Breast Cancer Introduction



13.1.4 AstraZeneca Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020))

13.1.5 AstraZeneca Recent Development

13.2 Sanofi

13.2.1 Sanofi Company Details

13.2.2 Sanofi Business Overview and Its Total Revenue

13.2.3 Sanofi ER Targeted Drugs for Breast Cancer Introduction

13.2.4 Sanofi Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020)

13.2.5 Sanofi Recent Development

13.3 Pfizer

13.3.1 Pfizer Company Details

13.3.2 Pfizer Business Overview and Its Total Revenue

13.3.3 Pfizer ER Targeted Drugs for Breast Cancer Introduction

13.3.4 Pfizer Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020)

13.3.5 Pfizer Recent Development

13.4 Mylan

13.4.1 Mylan Company Details

13.4.2 Mylan Business Overview and Its Total Revenue

13.4.3 Mylan ER Targeted Drugs for Breast Cancer Introduction

13.4.4 Mylan Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020)

13.4.5 Mylan Recent Development

13.5 Wockhardt

13.5.1 Wockhardt Company Details

13.5.2 Wockhardt Business Overview and Its Total Revenue

13.5.3 Wockhardt ER Targeted Drugs for Breast Cancer Introduction

13.5.4 Wockhardt Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020)

13.5.5 Wockhardt Recent Development

13.6 Cipla

13.6.1 Cipla Company Details

13.6.2 Cipla Business Overview and Its Total Revenue

13.6.3 Cipla ER Targeted Drugs for Breast Cancer Introduction

13.6.4 Cipla Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020)

13.6.5 Cipla Recent Development

13.7 Actiza Pharmaceutical

13.7.1 Actiza Pharmaceutical Company Details

13.7.2 Actiza Pharmaceutical Business Overview and Its Total Revenue

13.7.3 Actiza Pharmaceutical ER Targeted Drugs for Breast Cancer Introduction

13.7.4 Actiza Pharmaceutical Revenue in ER Targeted Drugs for Breast Cancer

## Business (2015-2020)

### 13.7.5 Actiza Pharmaceutical Recent Development

## 13.8 Teva

### 13.8.1 Teva Company Details

### 13.8.2 Teva Business Overview and Its Total Revenue

### 13.8.3 Teva ER Targeted Drugs for Breast Cancer Introduction

### 13.8.4 Teva Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020)

### 13.8.5 Teva Recent Development

## 13.9 Shanghai Forward Technology

### 13.9.1 Shanghai Forward Technology Company Details

### 13.9.2 Shanghai Forward Technology Business Overview and Its Total Revenue

### 13.9.3 Shanghai Forward Technology ER Targeted Drugs for Breast Cancer

## Introduction

### 13.9.4 Shanghai Forward Technology Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020)

### 13.9.5 Shanghai Forward Technology Recent Development

## 13.10 Bayer

### 13.10.1 Bayer Company Details

### 13.10.2 Bayer Business Overview and Its Total Revenue

### 13.10.3 Bayer ER Targeted Drugs for Breast Cancer Introduction

### 13.10.4 Bayer Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020)

### 13.10.5 Bayer Recent Development

## 13.11 Liaoning Kangtai Pharmaceutical

### 10.11.1 Liaoning Kangtai Pharmaceutical Company Details

### 10.11.2 Liaoning Kangtai Pharmaceutical Business Overview and Its Total Revenue

### 10.11.3 Liaoning Kangtai Pharmaceutical ER Targeted Drugs for Breast Cancer

## Introduction

### 10.11.4 Liaoning Kangtai Pharmaceutical Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020)

### 10.11.5 Liaoning Kangtai Pharmaceutical Recent Development

## 13.12 Fu 'an Pharmaceutical Group

### 10.12.1 Fu 'an Pharmaceutical Group Company Details

### 10.12.2 Fu 'an Pharmaceutical Group Business Overview and Its Total Revenue

### 10.12.3 Fu 'an Pharmaceutical Group ER Targeted Drugs for Breast Cancer

## Introduction

### 10.12.4 Fu 'an Pharmaceutical Group Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020)

### 10.12.5 Fu 'an Pharmaceutical Group Recent Development

### 13.13 Yangtze River Pharmaceutical Group

10.13.1 Yangtze River Pharmaceutical Group Company Details

10.13.2 Yangtze River Pharmaceutical Group Business Overview and Its Total Revenue

10.13.3 Yangtze River Pharmaceutical Group ER Targeted Drugs for Breast Cancer Introduction

10.13.4 Yangtze River Pharmaceutical Group Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020)

10.13.5 Yangtze River Pharmaceutical Group Recent Development

### 13.14 Amneal Pharms

10.14.1 Amneal Pharms Company Details

10.14.2 Amneal Pharms Business Overview and Its Total Revenue

10.14.3 Amneal Pharms ER Targeted Drugs for Breast Cancer Introduction

10.14.4 Amneal Pharms Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020)

10.14.5 Amneal Pharms Recent Development

### 13.15 Novartis

10.15.1 Novartis Company Details

10.15.2 Novartis Business Overview and Its Total Revenue

10.15.3 Novartis ER Targeted Drugs for Breast Cancer Introduction

10.15.4 Novartis Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020)

10.15.5 Novartis Recent Development

### 13.16 Intas Pharmaceuticals

10.16.1 Intas Pharmaceuticals Company Details

10.16.2 Intas Pharmaceuticals Business Overview and Its Total Revenue

10.16.3 Intas Pharmaceuticals ER Targeted Drugs for Breast Cancer Introduction

10.16.4 Intas Pharmaceuticals Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020)

10.16.5 Intas Pharmaceuticals Recent Development

### 13.17 Chemo

10.17.1 Chemo Company Details

10.17.2 Chemo Business Overview and Its Total Revenue

10.17.3 Chemo ER Targeted Drugs for Breast Cancer Introduction

10.17.4 Chemo Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020)

10.17.5 Chemo Recent Development

### 13.18 Accure Labs

10.18.1 Accure Labs Company Details

- 10.18.2 Accure Labs Business Overview and Its Total Revenue
- 10.18.3 Accure Labs ER Targeted Drugs for Breast Cancer Introduction
- 10.18.4 Accure Labs Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020)
- 10.18.5 Accure Labs Recent Development
- 13.19 Natco
  - 10.19.1 Natco Company Details
  - 10.19.2 Natco Business Overview and Its Total Revenue
  - 10.19.3 Natco ER Targeted Drugs for Breast Cancer Introduction
  - 10.19.4 Natco Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020)
  - 10.19.5 Natco Recent Development
- 13.20 Orion Corporation
  - 10.20.1 Orion Corporation Company Details
  - 10.20.2 Orion Corporation Business Overview and Its Total Revenue
  - 10.20.3 Orion Corporation ER Targeted Drugs for Breast Cancer Introduction
  - 10.20.4 Orion Corporation Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020)
  - 10.20.5 Orion Corporation Recent Development
- 13.21 Kyowa Hakko Kirin
  - 10.21.1 Kyowa Hakko Kirin Company Details
  - 10.21.2 Kyowa Hakko Kirin Business Overview and Its Total Revenue
  - 10.21.3 Kyowa Hakko Kirin ER Targeted Drugs for Breast Cancer Introduction
  - 10.21.4 Kyowa Hakko Kirin Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020)
  - 10.21.5 Kyowa Hakko Kirin Recent Development

## **14 ANALYST'S VIEWPOINTS/CONCLUSIONS**

## **15 APPENDIX**

- 15.1 Research Methodology
  - 15.1.1 Methodology/Research Approach
  - 15.1.2 Data Source
- 15.2 Disclaimer
- 15.3 Author Details

## List Of Tables

### LIST OF TABLES

Table 1. ER Targeted Drugs for Breast Cancer Key Market Segments

Table 2. Key Players Covered: Ranking by ER Targeted Drugs for Breast Cancer Revenue

Table 3. Ranking of Global Top ER Targeted Drugs for Breast Cancer Manufacturers by Revenue (US\$ Million) in 2019

Table 4. Global ER Targeted Drugs for Breast Cancer Market Size Growth Rate by Type (US\$ Million): 2020 VS 2026

Table 5. Key Players of Tamoxifen

Table 6. Key Players of Toremifene

Table 7. Key Players of Fulvestrant

Table 8. COVID-19 Impact Global Market: (Four ER Targeted Drugs for Breast Cancer Market Size Forecast Scenarios)

Table 9. Opportunities and Trends for ER Targeted Drugs for Breast Cancer Players in the COVID-19 Landscape

Table 10. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis

Table 11. Key Regions/Countries Measures against Covid-19 Impact

Table 12. Proposal for ER Targeted Drugs for Breast Cancer Players to Combat Covid-19 Impact

Table 13. Global ER Targeted Drugs for Breast Cancer Market Size Growth by Application (US\$ Million): 2020 VS 2026

Table 14. Global ER Targeted Drugs for Breast Cancer Market Size by Regions (US\$ Million): 2020 VS 2026

Table 15. Global ER Targeted Drugs for Breast Cancer Market Size by Regions (2015-2020) (US\$ Million)

Table 16. Global ER Targeted Drugs for Breast Cancer Market Share by Regions (2015-2020)

Table 17. Global ER Targeted Drugs for Breast Cancer Forecasted Market Size by Regions (2021-2026) (US\$ Million)

Table 18. Global ER Targeted Drugs for Breast Cancer Market Share by Regions (2021-2026)

Table 19. Market Top Trends

Table 20. Key Drivers: Impact Analysis

Table 21. Key Challenges

Table 22. ER Targeted Drugs for Breast Cancer Market Growth Strategy

Table 23. Main Points Interviewed from Key ER Targeted Drugs for Breast Cancer

## Players

Table 24. Global ER Targeted Drugs for Breast Cancer Revenue by Players (2015-2020) (Million US\$)

Table 25. Global ER Targeted Drugs for Breast Cancer Market Share by Players (2015-2020)

Table 26. Global Top ER Targeted Drugs for Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in ER Targeted Drugs for Breast Cancer as of 2019)

Table 27. Global ER Targeted Drugs for Breast Cancer by Players Market Concentration Ratio (CR5 and HHI)

Table 28. Key Players Headquarters and Area Served

Table 29. Key Players ER Targeted Drugs for Breast Cancer Product Solution and Service

Table 30. Date of Enter into ER Targeted Drugs for Breast Cancer Market

Table 31. Mergers & Acquisitions, Expansion Plans

Table 32. Global ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US\$)

Table 33. Global ER Targeted Drugs for Breast Cancer Market Size Share by Type (2015-2020)

Table 34. Global ER Targeted Drugs for Breast Cancer Revenue Market Share by Type (2021-2026)

Table 35. Global ER Targeted Drugs for Breast Cancer Market Size Share by Application (2015-2020)

Table 36. Global ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US\$)

Table 37. Global ER Targeted Drugs for Breast Cancer Market Size Share by Application (2021-2026)

Table 38. North America Key Players ER Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US\$)

Table 39. North America Key Players ER Targeted Drugs for Breast Cancer Market Share (2019-2020)

Table 40. North America ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US\$)

Table 41. North America ER Targeted Drugs for Breast Cancer Market Share by Type (2015-2020)

Table 42. North America ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US\$)

Table 43. North America ER Targeted Drugs for Breast Cancer Market Share by Application (2015-2020)



Table 44. Europe Key Players ER Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US\$)

Table 45. Europe Key Players ER Targeted Drugs for Breast Cancer Market Share (2019-2020)

Table 46. Europe ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US\$)

Table 47. Europe ER Targeted Drugs for Breast Cancer Market Share by Type (2015-2020)

Table 48. Europe ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US\$)

Table 49. Europe ER Targeted Drugs for Breast Cancer Market Share by Application (2015-2020)

Table 50. China Key Players ER Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US\$)

Table 51. China Key Players ER Targeted Drugs for Breast Cancer Market Share (2019-2020)

Table 52. China ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US\$)

Table 53. China ER Targeted Drugs for Breast Cancer Market Share by Type (2015-2020)

Table 54. China ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US\$)

Table 55. China ER Targeted Drugs for Breast Cancer Market Share by Application (2015-2020)

Table 56. Japan Key Players ER Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US\$)

Table 57. Japan Key Players ER Targeted Drugs for Breast Cancer Market Share (2019-2020)

Table 58. Japan ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US\$)

Table 59. Japan ER Targeted Drugs for Breast Cancer Market Share by Type (2015-2020)

Table 60. Japan ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US\$)

Table 61. Japan ER Targeted Drugs for Breast Cancer Market Share by Application (2015-2020)

Table 62. Southeast Asia Key Players ER Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US\$)

Table 63. Southeast Asia Key Players ER Targeted Drugs for Breast Cancer Market

Share (2019-2020)

Table 64. Southeast Asia ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US\$)

Table 65. Southeast Asia ER Targeted Drugs for Breast Cancer Market Share by Type (2015-2020)

Table 66. Southeast Asia ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US\$)

Table 67. Southeast Asia ER Targeted Drugs for Breast Cancer Market Share by Application (2015-2020)

Table 68. India Key Players ER Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US\$)

Table 69. India Key Players ER Targeted Drugs for Breast Cancer Market Share (2019-2020)

Table 70. India ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US\$)

Table 71. India ER Targeted Drugs for Breast Cancer Market Share by Type (2015-2020)

Table 72. India ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US\$)

Table 73. India ER Targeted Drugs for Breast Cancer Market Share by Application (2015-2020)

Table 74. Central & South America Key Players ER Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US\$)

Table 75. Central & South America Key Players ER Targeted Drugs for Breast Cancer Market Share (2019-2020)

Table 76. Central & South America ER Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US\$)

Table 77. Central & South America ER Targeted Drugs for Breast Cancer Market Share by Type (2015-2020)

Table 78. Central & South America ER Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US\$)

Table 79. Central & South America ER Targeted Drugs for Breast Cancer Market Share by Application (2015-2020)

Table 80. AstraZeneca Company Details

Table 81. AstraZeneca Business Overview

Table 82. AstraZeneca Product

Table 83. AstraZeneca Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

Table 84. AstraZeneca Recent Development



Table 85. Sanofi Company Details

Table 86. Sanofi Business Overview

Table 87. Sanofi Product

Table 88. Sanofi Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

Table 89. Sanofi Recent Development

Table 90. Pfizer Company Details

Table 91. Pfizer Business Overview

Table 92. Pfizer Product

Table 93. Pfizer Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

Table 94. Pfizer Recent Development

Table 95. Mylan Company Details

Table 96. Mylan Business Overview

Table 97. Mylan Product

Table 98. Mylan Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

Table 99. Mylan Recent Development

Table 100. Wockhardt Company Details

Table 101. Wockhardt Business Overview

Table 102. Wockhardt Product

Table 103. Wockhardt Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

Table 104. Wockhardt Recent Development

Table 105. Cipla Company Details

Table 106. Cipla Business Overview

Table 107. Cipla Product

Table 108. Cipla Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

Table 109. Cipla Recent Development

Table 110. Actiza Pharmaceutical Company Details

Table 111. Actiza Pharmaceutical Business Overview

Table 112. Actiza Pharmaceutical Product

Table 113. Actiza Pharmaceutical Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

Table 114. Actiza Pharmaceutical Recent Development

Table 115. Teva Business Overview

Table 116. Teva Product

Table 117. Teva Company Details

Table 118. Teva Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

Table 119. Teva Recent Development

Table 120. Shanghai Forward Technology Company Details

Table 121. Shanghai Forward Technology Business Overview

Table 122. Shanghai Forward Technology Product

Table 123. Shanghai Forward Technology Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

Table 124. Shanghai Forward Technology Recent Development

Table 125. Bayer Company Details

Table 126. Bayer Business Overview

Table 127. Bayer Product

Table 128. Bayer Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

Table 129. Bayer Recent Development

Table 130. Liaoning Kangtai Pharmaceutical Company Details

Table 131. Liaoning Kangtai Pharmaceutical Business Overview

Table 132. Liaoning Kangtai Pharmaceutical Product

Table 133. Liaoning Kangtai Pharmaceutical Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

Table 134. Liaoning Kangtai Pharmaceutical Recent Development

Table 135. Fu 'an Pharmaceutical Group Company Details

Table 136. Fu 'an Pharmaceutical Group Business Overview

Table 137. Fu 'an Pharmaceutical Group Product

Table 138. Fu 'an Pharmaceutical Group Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

Table 139. Fu 'an Pharmaceutical Group Recent Development

Table 140. Yangtze River Pharmaceutical Group Company Details

Table 141. Yangtze River Pharmaceutical Group Business Overview

Table 142. Yangtze River Pharmaceutical Group Product

Table 143. Yangtze River Pharmaceutical Group Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

Table 144. Yangtze River Pharmaceutical Group Recent Development

Table 145. Amneal Pharms Company Details

Table 146. Amneal Pharms Business Overview

Table 147. Amneal Pharms Product

Table 148. Amneal Pharms Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

Table 149. Amneal Pharms Recent Development

Table 150. Novartis Company Details

Table 151. Novartis Business Overview

Table 152. Novartis Product

Table 153. Novartis Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

Table 154. Novartis Recent Development

Table 155. Intas Pharmaceuticals Company Details

Table 156. Intas Pharmaceuticals Business Overview

Table 157. Intas Pharmaceuticals Product

Table 158. Intas Pharmaceuticals Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

Table 159. Intas Pharmaceuticals Recent Development

Table 160. Chemo Company Details

Table 161. Chemo Business Overview

Table 162. Chemo Product

Table 163. Chemo Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

Table 164. Chemo Recent Development

Table 165. Accure Labs Company Details

Table 166. Accure Labs Business Overview

Table 167. Accure Labs Product

Table 168. Accure Labs Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

Table 169. Accure Labs Recent Development

Table 170. Natco Company Details

Table 171. Natco Business Overview

Table 172. Natco Product

Table 173. Natco Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

Table 174. Natco Recent Development

Table 175. Orion Corporation Company Details

Table 176. Orion Corporation Business Overview

Table 177. Orion Corporation Product

Table 178. Orion Corporation Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

Table 179. Orion Corporation Recent Development

Table 180. Kyowa Hakko Kirin Company Details

Table 181. Kyowa Hakko Kirin Business Overview

Table 182. Kyowa Hakko Kirin Product

Table 183. Kyowa Hakko Kirin Revenue in ER Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

Table 184. Kyowa Hakko Kirin Recent Development

Table 185. Research Programs/Design for This Report

Table 186. Key Data Information from Secondary Sources

Table 187. Key Data Information from Primary Sources

## List Of Figures

### LIST OF FIGURES

Figure 1. Global ER Targeted Drugs for Breast Cancer Market Share by Type: 2020 VS 2026

Figure 2. Tamoxifen Features

Figure 3. Toremifene Features

Figure 4. Fulvestrant Features

Figure 5. Global ER Targeted Drugs for Breast Cancer Market Share by Application: 2020 VS 2026

Figure 6. Hospital Case Studies

Figure 7. Clinic Case Studies

Figure 8. Drug Center Case Studies

Figure 9. Other Case Studies

Figure 10. ER Targeted Drugs for Breast Cancer Report Years Considered

Figure 11. Global ER Targeted Drugs for Breast Cancer Market Size YoY Growth 2015-2026 (US\$ Million)

Figure 12. Global ER Targeted Drugs for Breast Cancer Market Share by Regions: 2020 VS 2026

Figure 13. Global ER Targeted Drugs for Breast Cancer Market Share by Regions (2021-2026)

Figure 14. Porter's Five Forces Analysis

Figure 15. Global ER Targeted Drugs for Breast Cancer Market Share by Players in 2019

Figure 16. Global Top ER Targeted Drugs for Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in ER Targeted Drugs for Breast Cancer as of 2019)

Figure 17. The Top 10 and 5 Players Market Share by ER Targeted Drugs for Breast Cancer Revenue in 2019

Figure 18. North America ER Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US\$)

Figure 19. Europe ER Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US\$)

Figure 20. China ER Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US\$)

Figure 21. Japan ER Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US\$)

Figure 22. Southeast Asia ER Targeted Drugs for Breast Cancer Market Size YoY

Growth (2015-2020) (Million US\$)

Figure 23. India ER Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US\$)

Figure 24. Central & South America ER Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US\$)

Figure 25. AstraZeneca Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 26. AstraZeneca Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 27. Sanofi Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 28. Sanofi Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 29. Pfizer Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 30. Pfizer Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 31. Mylan Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 32. Mylan Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 33. Wockhardt Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 34. Wockhardt Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 35. Cipla Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 36. Cipla Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 37. Actiza Pharmaceutical Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 38. Actiza Pharmaceutical Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 39. Teva Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 40. Teva Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 41. Shanghai Forward Technology Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 42. Shanghai Forward Technology Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 43. Bayer Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 44. Bayer Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 45. Liaoning Kangtai Pharmaceutical Total Revenue (US\$ Million): 2019 Compared with 2018



Figure 46. Liaoning Kangtai Pharmaceutical Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 47. Fu 'an Pharmaceutical Group Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 48. Fu 'an Pharmaceutical Group Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 49. Yangtze River Pharmaceutical Group Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 50. Yangtze River Pharmaceutical Group Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 51. Amneal Pharms Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 52. Amneal Pharms Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 53. Novartis Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 54. Novartis Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 55. Intas Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 56. Intas Pharmaceuticals Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 57. Chemo Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 58. Chemo Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 59. Accure Labs Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 60. Accure Labs Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 61. Natco Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 62. Natco Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 63. Orion Corporation Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 64. Orion Corporation Revenue Growth Rate in ER Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

## I would like to order

Product name: COVID-19 Impact on Global ER Targeted Drugs for Breast Cancer Market Size, Status and Forecast 2020-2026

Product link: <https://marketpublishers.com/r/C9782E999321EN.html>

Price: US\$ 3,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C9782E999321EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



